Why the study?
Direct oral factor Xa inhibitors interfere with lupus anticoagulant assays, challenging the diagnosis of antiphospholipid syndrome in treated patients.
Does the DOAC Filter effectively remove FXa inhibitors from plasma samples without affecting lupus anticoagulant testing?
Population
Patient plasma samples: 38 rivaroxaban, 41 apixaban, and 68 without anticoagulant
Comparison
Samples before vs after filtration with DOAC Filter
Design
In vitro diagnostic study
Authors
Loading...
DOAC Filter may enable LA testing during FXa inhibitor therapy; leaves open validation in larger APS cohorts before adoption.
Does the DOAC Filter effectively remove FXa inhibitors from plasma samples without affecting lupus anticoagulant testing?
The DOAC Filter effectively removes rivaroxaban and apixaban from plasma samples, preventing their interference with lupus anticoagulant testing.
Farkh et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: